Braveheart Bolsters Biotech Influence with New Agreements

Braveheart Investment (GB:BRH) has released an update.

Braveheart Investment Group has announced updates on two key portfolio companies, Kirkstall and Paraytec. Kirkstall has expanded its reach in the Chinese market with a new exclusive distribution agreement for its Quasi Vivo products, aimed at reducing the need for animal testing in drug safety assessments. Meanwhile, Paraytec has patented a method that significantly accelerates bacteria detection in human blood, offering potential for future royalty income through licensing to other manufacturers.

For further insights into GB:BRH stock, check out TipRanks’ Stock Analysis page.